论文部分内容阅读
目的探讨产前应用盐酸氨溴索与地塞米松在促胎肺成熟中的应用价值。方法回顾性分析孕28～36周因早产或计划早产分娩的孕妇180例,分为盐酸氨溴索组和地塞米松组,产前应用盐酸氨溴索或地塞米松促胎肺成熟治疗,观察不同孕周早产儿RDS的发生率。结果盐酸氨溴索组孕31周前出生的早产儿RDS发生率显著低于地塞米松组(P<0.05),两组在孕31～36周出生的早产儿RDS发生率无显著性差异(P>0.05)。结论产前应用盐酸氨溴索促胎肺成熟,在预防31周前出生的早产儿发生RDS方面显著优于地塞米松。
Objective To investigate the value of prenatal ambroxol hydrochloride and dexamethasone in promoting fetal lung maturation. Methods A retrospective analysis of pregnant women 28 ~ 36 weeks pregnant premature delivery or planned delivery of 180 pregnant women, divided into ambroxol hydrochloride group and dexamethasone group, prenatal application of ambroxol hydrochloride or dexamethasone to promote fetal lung maturation therapy, Observe the incidence of RDS in different gestational weeks. Results The incidence of RDS in preterm infants born ambroxol hydrochloride group before pregnancy was significantly lower than that in dexamethasone group (P <0.05). There was no significant difference in the incidence of RDS among preterm infants born between 31 and 36 weeks’ P> 0.05). Conclusions Prenatal application of ambroxol hydrochloride promotes fetal lung maturation and is significantly superior to dexamethasone in RDS in preterm infants born 31 weeks prior to prophylaxis.